Business
Grey Matters Health Signs LOI with Catalyst MedTech for 200 Brain PET Scans for Alzheimer’s Clinical Trial at 2nd NovaScan Location Planned for Tampa
VANCOUVER, British Columbia, May 20, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: GREY) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce that it has signed a non-binding Letter of Intent (LOI) with Catalyst MedTech (Catalyst), to provide a minimum of 200 brain Positron Emission Tomography (PET) scans for an upcoming Alzheimer’s Disease (AD) clinical trial, to be conducted by an international Contract Research Org
About this update from Grey Matters Health Inc
[{"type":"image","alt":"Grey Matters Health Inc.","displaySize":"","headline":null,"caption":"Grey Matters Health Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":253,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/edf60a848081d4938c0fd75014ed5315"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QEzKjbzdFJCgmD0r.y982A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNg--/https://media.zenfs.com/en/globenewswire.com/edf60a848081d4938c0fd75014ed5315","width":253,"height":70},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/QEzKjbzdFJCgmD0r.y982A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNg--/https://media.zenfs.com/en/globenewswire.com/edf60a848081d4938c0fd75014ed5315","width":253,"height":70}},"lazy":false},{"type":"text","content":"VANCOUVER, British Columbia, May 20, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: GREY) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce that it has signed a non-binding Letter of Intent (LOI) with Catalyst MedTech (Catalyst), to provide a minimum of 200 brain Positron Emission Tomography (PET) scans for an upcoming Alzheimer’s Disease (AD) clinical trial, to be conducted by an international Contract Research Organization (CRO) specializing in AD research. The PET Scans will be performed at the Company’s NovaScan Neuroimaging Clinics™ second location planned for Tampa, Florida. The parties will work towards signing a definitive services agreement in the next 60 days.","length":764,"tagName":"p"},{"type":"text","content":"Clinical trials for new AD drugs that require patients to have a positive AD diagnosis as part of the study, must include a confirmation of AD by either a spinal tap or a brain PET scan utilizing an isotopic tracer. A brain PET scan involves taking a series of pictures of the brain after the patient is injected with radioactive isotopes, to determine the presence and level of AD involvement. Compared to a spinal tap, a brain PET scan is considered a far less invasive and preferred procedure.","length":496,"tagName":"p"},{"type":"text","content":"“A services agreement with Catalyst MedTech for a minimum of 200 brain PET scans in our first year of operation for our planned second Florida location in Tampa, will provide a significant base of initial revenue,” said Christopher J. Moreau CE...